Latest Breaking News On - United kingdom the university - Page 3 : vimarsana.com

– In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.   AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism. CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna will now start the formal preclin

United kingdomJenene thomasAeterna zentaris gmbRichardj rossKlaus pauliniUnited kingdom the universityAeterna zentarisCompany on twitterEuropean commissionUniversity of sheffieldExchange commissionAeterna zentaris incEuropean unionNovo nordiskAeterna zentaris gmbhChief executive officer